Document 6wz74aBjoDZXn4g7GkarZvQwo

2S PP R26 _ 144] TAFT, STETTINIUS & HOLLISTER LLP 425 WALNUT STREET. SUITE 1800 ARERCEEIRVERD s13-281-2000 03AUG-1 RHIO:LO ses p R EHR mR-268605 0800i5y 331-2000080372 Eo. we elHl s Ece TELECOPY AND FEDERAL EXPRESS -%0-377% %H@ 3 32 Richard H. Hefter, Chief HUSi.gh EPnrvoidruocntmieonntValolPurmoteecCthieomniAcgalesncByranch O1f2f0i0cePeonfnPsoylllvuatniiona PArveevneunet,ioNn.Wa.nd Toxics Washington, D.C. 20460-0001 Document Processing Center (7407M) EU.PSA. EEnavsitr-onRmoeonmta6l4P2r8otAetcttn:ionSeAcgteionncy8(e) O1f2f0i0cePeonfnPsoylllvuatniiona PArveevneunet,ioNn.Wa.nd Toxics Washington, D.C. 20460-0001 Re: TSCA Section 8(c) Reporting For PFOA Dear Mr. Hefter: "This letter serves as a supplement to our letotfJeulry 3, 2003, in conneetion with the rNeefmeoreunrcsedanmdatCtoemrpparnovyi'dsin(g"DaudPdointti'osn"a)l kinnfoowrlmeadtgioenorfehleatailntgh teofftehcetsexrteelnattoedfEt.oIe.xpdousPuornettdoe `ammonium perfluorooctanoate (a/k/a APFO/PFOA/FC-143/C-8) (hereinafter "C-8") at the time that DuPont obtained the pregnancy outcome and drinking water contamination information referenced in our July 3, 2003 letter. Becauseofthe potential likelihoodof substantial harm to our Class members or the public interest from a lackof complete information on this topic, we submit the following additional supplemental information obtained from DuPont for areconsideration in connection counsel on this matter in its with June y2o0,ur20A0g3e,nclyet'tserevraelsupaotnidoinnsgotfo tyhoeusrtMataeyme2n2t,s made 2003, bleyttDeur Poonntt'hiss 1 rNeovvieemwobfearva9,il1a9b6l1e-inDfuoPromnatt'isoTnorxeilcatoilnoggtyo SteocxtiiciotnyCohfieTfe,flDoornotdhiyspB.ersHionogda,geunptosn, concluded that C-8 has "the ability to increase the size of the liverofrats at low doses," and "recommended that. . . these materials . .. be handled with extreme care. Contact with the skin should be strictly avoided." (Exhibit A (HLAB000232-233)) ins Ngiepnai-aonrs Contai"n NO Cay 0008118631 00001 g Zo -= = 33 =z ac > ~ Richard Hefter July 31,2003 Page2 2. Febuary 14, 1962 - DuPont studies on C-8 in rats "proved lethal in high dose concentrations through injuryto the stomach, intestine, brain, lung and pancreas. At lower dose concentrations the chemical induced enlargementofthe liver, pancreas and kidney, the least dose which included a change in liver being 1.5 mg/kg" (Exhibit A (HLAB000240)) 3. August 19, 196-5 DuPont's medical research projects on the effectsof C-8 and related chemicals on the livers of rats and dogs confirmed that "the most striking abnormality in animals surviving a single sub-lethal dose was gross enlargement ofthe liver." (Exhibit B (HLAB000003-20)) 4. Aug3u1,1s96t6 - DuPont determined that "(sJome of the solids wastes from the Fine Powder and Dispersion Area of the [DuPont Washington Works) "Teflon" plant contain small amount of toxic perfluorocarboxylic dispersing agents" and that "[wlithout a pretreatment, a small amountofthe perfluorocarboxylic acid dispersing agent would be leached into the groundwater." (Exhibit C (EIDI93614-8) 5. Qctober 28, 1966 - DuPont's Washington Works decided that wet "Teflon scrap is no longer going to the city land-fil" and that "[a]ll wet "Teflon containing C- or C-9 dispersing agents (must be kept on the plantfordisposal at sea at a future date)." (Exhibit D (EID193613)) 6. Ecbruary I8, 1970 - DuPont's Washington Works plant sent a memo to DuPont's Experimental Station in Wilmington, Delaware stating that; Past studies made at Haskell Laboratory have indicated that ammonium perfluorooctanoate (C-8 APEC), which is used in the preparation of Teflon" dispersions, is highly toxic when inhaled and moderately toxic when injected. ... We are interested in determining the systemic effect for repetitious skin contacts of short duration with C-8 APFC powder and with the aqueous dispersion of polytetrafluorocthylene containing C-8 (or chlorendic acid). We are also interested in determining the chronic effect of inhalation of minute quantitiesof C-8 APFC. In addition to knowing these effects, we would like guidance on woos 000002 Richard Hefler July 31,2003 Page3 the personnel equipment necessary for adequate protection against these effects. (Exhibit E (EID123138-43)) 7. Mays, 1970- DuPont' Bio-Sciences Group Research Manager informed DuPont's Washington Works plant that "C-8 APFC and C-9 APFC cause liver enlargement, but we don't know what is the lowest repeated oral dosage that will cause it. We have no repeated oral dosagestudyto indicate if C-8 APFC or C-9 APFC accumulates in the body to toxic levels. We do not know the eye or skin imitation potential for C-8 APFC or C-9 APFC and we do not know whether the liver enlargement effect occurs in rats or in other species as well." (Exhibit F (EID072196-99)) After summarizing the potential studies necessary to acquire the missing toxicology information, DuPont's Bio-Sciences Group Research Manager informed DuPont's Washington Worksplant that "none of the repeated inhalation studies would be necessary" "ifyou can eliminate continuous exposure 10 C-8 APFC by inhalation." "Similarly, eliminationofrepeated exposure by skin absorption would eliminate the need for a repeated skin absorption toxicity study." (1d) 8 1975 - DuPont completed a Study of Myocardial Infarction at Washington Works Plant "to evaluate the incidenceofcasesofmyocardial infarction among male wage and salary roll employees at the Washington Works Plant from 1956 to 1973 because some workers had complained that the occurrenceofheart attacks among employees seemed excessive." (Exhibit G (EID713127-35)) DuPont's study concluded that: Among salaried employees, the observed incidence of myocardial infarction is significantly higher than the expected number...The high overall incidence is largely the resultofelevated rates in recent years. In the period from 1971 to 1973, the difference between observed and predicted numbers is great 12 observed cases verus 5.3 expected cases (P = 0.008). .... Further investigationofoccupation reveals that the high frequency of M.L cases among salaried employees is seen largely in foreman. .. Patrolman,a group representing three percentof the Washington Works population, also showed a somewhat elevated incidence of M.I wonassst.1 000003 Richard Hefter July 31,2003 Paged (Jd) With respect to the increased rate of M.I. among salaried foreman, DuPont concluded that "increased incidence in this group cannot be explained by their age distribution." (id) 9. May5, 1978 - In connection with an upcoming meeting with 3M on May 30, 1975, DuPont's Haskell Laboratory forwarded to DuPont's Medical Director, Dr. Bruce Karrh, a copyofan article published in 1976 entitled "Organic FluoroCompounds in Human Plasma: Prevalence and Characterization." (Exhibit H (EID107111-29)) In the 1976 study, the authors collected plasma samples from "106 individuals living in five different cities with between 0.1 and 5.6 ppm fluoride in their public water supply." (Id., at EID107113) The "[hjuman plasma was obtained from blood banks in five cities." (/d., at EIDI07116) The five cities included in the blood study were Albany, New York, Rochester, New York, Corpus Christi, Texas, Hillsboro, Texas, and Andrews, Texas. (Id, at EID107121) Analysisof the blood samples revealed "chemical shifts" consistent `with C-8 and shifts "consistent with the presenceofamide or ester derivatives, or possibly with the presence ofa sulfonic acid derivative as the functional group. One explanation for the additional peaks in the spectrum is the presence of branched isomers." (Id. at EID107124) The authorsofthe 1976 study concluded that: These findings suggest that there is widespread contamination of human tissues with trace amounts of organic fluorocompounds derived from commercial products. All available information on this subject is in accordance with this interpretation. A seriesofcompounds havinag structure consistent with that found here for the predominate formoforganic fluorine in human plasma is widely used commercially for their potent surfactant properties. For example, they are used as water and oil repellents in the treatment of fabrics and leather. Other uses include the production of waxed paper and formulation of floor waxes. The findings presented here that the concentrationoforganic fluorine was not related to the concentrationof inorganic fluoride either in blood or in the public water supply, and the early finding that they was litle or no organic fluorine in the blood of animals other than human are all in Keeping with environmental sources such as these. 000004 Richard Hefter July 31,2003 Page 5 `The prevalenceoforganic fluorine in human plasma is probably quite high since 104 of the 106 plasma samples tested here and all 35 in an earlier study had measurable quantities. The prevalenceof the particular compounds isolated and characterized here, ic., perfluoro fatty acid (C6 - C-8) derivatives, is not known since the starting `material for cach batch shown... was pooled from between 25 and 30 individuals and since only about one thirdofthe original organic fluorine content was accounted for in the fractions containing these compounds. (Id, at 107126-7) 10. June 16, 1978 - DuPont reported that the 3M Company "has reported finding wFoCr1k4er3s.p"lus(EoxthhiebritunIid(eEnItDi0f8ie0d22f9l-u3o1ro)c)heImnirceaslpsoninset,heDubPloonotd'osfpMoetdeinctailalDliyreecxtpoors,ed Dr. Bruce persons Karrh, recommended [who currently work that DuPont "[rJeview or have worked jobs in the medical which there recordsofall is or was . potential for exposure to "Telomer A and its non-polymeric derivatives" still etrmepnldso.y"eadnbdytDoubPeognitn,obltoaoikniinnggf"obrlcooondsifsltueonrtoocrheumniucsaulallehveealltshoofcecxuprroesnecdesanodr unexposed workers. (/d) 11. June 22, 1978 - DuPont initiated a program to inform employeesofits Chambers `Weomrpklso,yeNees wanJderDsuePyonftac'isliptyroogfr3aMm'stofbiengdiinngoanfaloyrzgianngicthfelubolroioned ainndthmeebdliocoadl of its records ofChambers Works employees exposed to Telomer A sold under the 4"6Z)o)nyl""DutProandtemaalrsko. in(fEoxhrimbeidtiJts(CEhIaDm11b0e6r5s1-W3o)r)ks(S"eseupaelrsvoisEixohni"biatt Kthe(EtIiDm0e8t0h2at41- the testing was prompted bya "1976 report [referenced in the memo as the one ainutthhoerUe.dS.bycoGnutya,inestatlra] cinqduiacnattiitniges"otfhaftltuhoeribnleooind bsoetrhuomrogfantihce agnenderianlorpgoapnuilcation form" and that the "concentrationofinorganic fluorine has been shown to be rreelaadtyedextpolfalnuaotriiodne fioorntihnewparteesrenscueppolfioersg(annaitucraflluaonridnea.d"d(eEdx)h"ibbiutt Jt,haatt "E[I(JDhe1r1e0i6s5n3o) In response to the anticipated question of:"Will DuPont be informing the a`wpapsr:op"rAitattheirsepgouilnattoirnytaigmeencwieessoefe nhoissisgintiufaitciaonnt?"risDkuaPsosnotc'iastperdewpiatrhedthreesfplouonrsiene content in years and the blood. The existenceoffluorine in blood is published in open literature." (Exhibit K. at has been known EID 080245) for 10 woos. 00000 Richard Hefler July 31,2003 Page 6 12. AWuagsuhsitng3t, o1n9W7o-8rkDsuPpolanntt'sthMaetdDiucPaolnDtirreecctoorm,mDern. dBerduc"tehKeasrarhm,eamdevdiisceadlDuPont's tsuhrrvoeuiglhlapnrcoedpucrtoigornaomf"TfeofrlDounPoanntd'sFEWPasdhiispnegrtsoinonWsotrhaktsDer.mpKlaoryreheshaedxposed to C-8 recommended through Zonyl for the DuPont Chambers Works employees production. (ExhibitL (EID080236-40)) exposed to Telomers 13. SPeopwtere,mbperrep2a0,red19a7m8e-mDouPsounmtmaWraiszhiinnggthoisn "WroervikeswoMfetdhiecamleDdiirceacltorre,coDrrd.sYoofunger helaevveehnaodpelroantgo-rtsearmndexcpigohstuereentloaCb-o8r.a"tori(aEnxshi[baittthMe W(aEsIhD0i8n0g2t3o3n-W4)o)rkDsr.PlPaontw]erwho concluded that [Als you would anticipate, a great variety of illnesses and physical findings were found . [slomeofthe illnesses found are two heart attacks and five employees with high blood pressure. One questionable caseofskin cancer was found during an employee's physical examination in 1976. No further mentionof thispossible tumor could be found. Minor clevations of many blood tests did occur in larger-than-anticipated numbers. .... One of the liver function tests (SGOT) is most frequently elevated in the operator group. ... Since it has been previously determined that C-8 is an hepatatoxin, it iasndpocsesritbalienltyhantoCt-c8limniacyallbyeacpapuasrienntg,vetorxyicmienfifmecatls,to the liver. [23) 14. `Dmeecmeombseurmm22a,riz1i9n78g-DDuPuoPnotn'ts's"MCehdaimcbaelrsDiWreocrtkors,FDlru.orBorsuuclefaKcatrarnht,[spirce]pSatrueddya," stating that study, with "there does not seem a possible exception to of be an any adverse effect on the health liver." effects reported (Exhibit N in this (EID096510)) 15. ECe8brruaatrtyox7.ici1t9y79st-ud3yManfdor3wMa'rsde9d0-todaDyuPsounbtaccuotpeiCe-s8ofRh3Me'ssusnmeown9k0e-ydatyoxsiucbitaycute study. (Exhibit O (EID071855)) woozossi 1 000006 Richard Hefler July 31,2003 Page 7 16. March agreed 5, 1979 that there DuPont reviewed 3M's are compound-related new C-8 rat and effects indicated monkey studies in both studics, and and that a3dMdiitnitonhael taedxvteorfsetheeffsetcutdsieas.ppa(renEtlyxwPehr(eEiIrDev1be2a3li1e3d3ti)n)the data but not reported by 17. March 15, 1979 - DuPont's Epidemiology Section Manager, Sidney Pell, prepared `i2nmciedmenocesuimn mtahrei[zTienlgom"aerta/bZuolnaytli)onoexfptohseedDainspdecnosnatrryolVigsriotuspasn"datDiDsuaPboilnitt'ys Wage Chambers Works facility. (Exhibit Q (GK000378-79)) Mr. Pell found that: In the category, "Allergic, Endocrine, and the Metabolic" disorders, a significantly higher incidence was found in the exposed group for both Dispensary Visits and Disability Wage incidents. "This was attributed in the report to a higher number of diabetics in the exposed group. The exposed `group also showed significantly higher numbers for "mental and psychoneurotic" disorders and for disordersof "skin andcellular tissues." Explanations for these differences cannot be found from the available data. .... Although the number ofemployees with abnormal liver function tests was notably higher in the exposed group (6 compared to 1), the difference is not statistically significant (P <0.05). Nevertheless, the data do suggest that the exposed group may be at an excess risk of developing liver discase, so continued surveillance would be advisable. dy 18. rMeapoyrt22co,n1f9i7r9mi-nDgutPhoanttDupProenpatr'esdbalo"oSdtatteusstiRnegvhiaedw:deFtleucotreodcohregmainciaclsfliunorBilnoeoidn"a e"cmopnltoryoelegsroatupb"etowfperenes0u-m0a.3b8lyp"pnmon(-aevxepraogseedo"f0D.u0P9o4ntppWmi)l,mianngdttohna,t DDuePlaownatrhead detected organic fluorine in the employees at a rangeof0-0.37 bloodofits Chambers Works, New Jersey ppm (average of 0.15 ppm), with on individual in itnhebl"oWoidl.mi(nEgxthiobnitCoRnt(rEoIlDG8r0o2u74p)")tesBteicnagaussehtihgehlaesve1l0s.o6foprpgmanfiocr ofrlguaonriincefilnuotrhiene blood of DuPont's Chambers Works employees were not viewed as significantly wonossi1 000007 Richard Hefter July 31,2003 Page driefcfoermemnetnfdraotmiotnhew"acsonmtarodlegtroo"udpisocfoWntiilnmuienpgrtoognr,aDmetloadweatreeremimnpelofylueosr,intehien bulnoiofdo,rmaldyvifsaevoermapblloeyreeessultthsa"t b(lAod,odatanEaIlDys0i8s0p2r8o2g)ra(mSeheaaslbseoeEnxhdiibsictonStinued due to (EID080267-70)) 19. July 20, organic f1l9u7or9in-eDbulPooondttersetpirnegseanntdathievaelsthmesttudwiietsh. 3M to (See discuss Exhibit the status of U (EID107173) Dpeurrfilnugcrtohoecmtaeneotiicngac"id3M(FdCe-s1c4r3i)beidn ablgoaosd,churroinmea,toligvrear,phaincdmoetthehrodbitoolodgeitcealrmine materials. during the It can measure as meeting that "3M gliottleblaoso1d.s5papmbp.l"es(ifdr)om38MpealassoandtisscilnoaseCdhitoneDsuePont (v0il.l0a0g4e-03.001mi7lpepsmf)r,otmhCaannvtaolnu.esTfhoeunodrgiannidcevfelluoopriendecwoausntsriigensif(iec.agn,tl3yMlofwoeurnd 0D.u0P0o2n-t0.a1l3soinap1p0a6remnetmlybeprlsaonnfedthteo gdeinsecruasls Uw.iSt.hp3oMpultahteiroenp)o.rta(bIid.liattyofEtIhD1e0b7l1o7o4d) d(aEtIaD1i0nf7o1r9m4a.t9i5o)n)to U.S. EPA under TSCA Section 8(c). (See Exhibit T 20. wJuolryk2r5e,l1at9i7n9g t-oDourPgoannitcpfrleupaorreodcoammpoeumnodrsainndhuummsaunmbmlaoroidz,iinngditchaetsitnagttuhsaotfortgsanic bfleutowreienen l0.e4velasndha2d1.b1eepnpmd.ete(cEtxehdibiintDVuP(oEnItD1W0a7s1h9i9n)g)toTnhWeomrekmsoermapnldoyuemesalasto bceocnafuisremefdlutohraitnDeuiPnobnltoo"d(dpeercisdeewdansotditsoclreopsoerdt to in EPA 1976 under article 8(c) and of TOSCA because no [sic] advarse Exhibit hWea(ltEhIDef1f0e7ct19is6k)nown, therefore, no substantial risk." (/d. See also 21. July 30,1979 - DuPont prepared a memorandum summarizing information driescecnutssbeldoowditdhat3aMtooUn.SJ.ulEyP2A6., 1(9E7x8h,ibiintclWudi(nEgIDDuP1o0n7t1'9s6d)eDcuisriionngntohteto report the. conversation with 3M, DuPont: Advised Robert Prokop of3Mof our c`goenncelrualsipornasctwiicteohfrreegpaorrdttiongSeocrtiootnhe8r(wi)saend our pruebqluiicriezditnogbreelreevpaonrttefdinudnidngesreSveecntiifonth8e(cy).are not w[hEautgepnleanBse3rmManhaodfwDiuthPorneg]aradskteodpuPbrloikcoizpintog ctlhairsify worst. 000008 Richard Hefter July 31,2003 Page 9 fluorine blood level information and/or directly advisingthe relevant health agencyofthis information. Prokop indicated that he believed 3M wasfavorablydisposed toward disclosing this information and promised a more definitive response next week after reviewing the matter with Lester Krogh (3M's Division Vice President) [23] 21. August 28,1979 - DuPont Epidemiologist, William E. Fayerweather sent a memo to DuPont Washington Works' Medical Director, Dr. Younger Power, stating that DfuunPcotnito'nsteMsetdriecsualltsDifroercwtoorr,keDrr.s BwrituhceC-K8arerxhp,ohsuardea,saknedd h[tihmat"Dtro. lYoookunignetor]thPeolwieverr asked me to examine myocardial Fayerweather concluded that infarction cases and deaths at the Plant. Mr. My preliminary results suggest that C-8 exposed workers may possibly have positive liver function tests more often than the plant population as a whole, and that the number of active wage role employees having myocardial infarctions from 1974 through 1977 was somewhat higher than was. expected based on company-wide experience. Asa consequenceof these preliminary findings, the following steps are being taken: (1) Liver function survey . (2) Coronary heart disease mortality [study] (Exhibit X (ED080214-15)) 22. October, 1979 - DuPont prepared tables summarizing the levelsof organic fluorine detected in Washington Works employee blood. (See Exhibits Y (EID080255-60), Z (EID080732-37), and AA (EID107158-60) 23. January 17, 1980 - DuPont obtained organic fluoride levels in blood from `ormgeacnhiacnifclsuoatriintes WinasthheinegmtploonyeWeosr'kbslopolda.nt,(iEnxdhiicbaittinBgBan(EaIvDe0rSa0ge19o3f)0).66 ppm woossi1 000009 Richard Hefler July 31,2003 Page 10 24. pJraenpuaarreyd28a,m1e9m8o0 -suDmumPaornitz'isnAgssciosntcalnutsiMoendsicraelacDhierdecbtyorD,uDPr.onVtadnunriBnrgewastmeere,ting on January 25, 1980 to discuss an ongoing "Liver Enzyme Study of Workers Enoxtpeodsethdatto"tCh-e8maetaPnarSkeGrOsbTurign.t"he(ETxFhEibiptroCceCss(EoIpDer0a9t9o4r3g3r-o3u4p))anDdr.thBeremwesatnerAP tihnatth"ewFeEaPrepruoncaebslsegtrooeuxpplaarienewlehvyatoendlwyhtehenmceoamnpaSreGdOtTo wotohuelrdpblaenetlgervoautepds"inaonnde `group and only the mean AP would be elevated in another group." (/d.) 25. Fteobtarlu,airnyor2g5a,ni1c,98a0nd- oDrugPaonnitc pfrlueoprairneedian wmoermkoerrabnldouodmastutmsmaSrpiruzainncge,thVeirregsiunlitas of plant. (Exhibit EE (EID107155-56)) 26. tFoetbalruaanrdyo2r8,gan1i9c80fl-uoDruiPneonitn wporerpkaerredblaoomdeminorrealnatdiuonmshsiupmtmoawroirzkipnlgatcheeCl-e8vealisrof Tevels at (Exhibit DuPont's Toledo, DD (EID079084)) Philadelphia, Marshall Lab, and Fairfield sites. 27. March 3, 1980 - DuPont prepared a memorandum summarizing the level of oWriglamniincgtfoluno,riDneeldaewtaercet,edChinamthbeebrlsoWoodorfkis,tsEexpmeprliomyeenetsalatSittastWioans,hianndgtSopnruWaonrckes, facilities, along with DuPont's "Finishes Plants." (Exhibit FF (EID079036)) 28. June, 1980 - DuPont's Assistant Medical Director, Dr. Vann Brewster, prepared WamsehimnogteoxpnrWesosriknsg ehimspcloonyceeersnrtehgaatradidnrgaftthceoomumtucnoimceatoifoDnuPtoonDtu'Psonltiv'esr study of teemsptslooyneathso"siemepmlipelsoytheaetstphoeteMnetdiiacllayleDxipvoisseidontowiCl-l8n.o"t (cEoxnhtiibniuteGthGe s(tEuIdDy10o2f47li7v)e)r, In response, Dr. Brewster states that: Even though we have found no "conclusive: evidence ofa occupationally related health problem," we still cannot explain why the mean wSoGrOkeTrswaasndsitghnaitftihceanmtleyahnigAhPerwaamsosniggnTifFicEanptrloycess higher among FEP process and service workers. Tthheerderfaoftr:e,AItrtehceoemnmdeofndthtehesfeoclolnodwipnagracghraanpghe,s..to oafddl:iver"Htoewsetsvecron,tiitnuwea.s" r[eancdo]m[mae]tndtheedbtohtattotmheosftudy woazassi.1 000010 Richard Hefler July 31,2003 Page 11 a pliavgeer t2e,satsdodfaemfpoulrotyheietsem:wi"thCopnottienntuiealtoeexvpaolsuuartee ttohe (rd) 29. Jaunl"yO3ut1l,i1n9e,80Ta-lDku&PoCnhtarctosn.d"uc(tEexdhiabi"tCH-8Hco(mEmIuD0n7i9c3a9t9i-o4n1s8m)e)etIinntgh"osaend provided documents, DuPont confirmed that People working with C-8 generally "C-8 is toxic but can be handled safely. accumulate organic fluorine in the blood, and nleovealdsvegresneerhaelallytchoerfrfeelcattse,wciotnhtijnoubeedxepxopsousruerpeotiesntnioatl.tolAelratbhloeu."gh(dth.i,sahtas caused EID079401. See also Exhibit I (EID077237-62)) 30. Nbloovoedmbreesru,lts1,9i8n0cl-uDduiPngonatnperwepaanraelydsainsoafntahlyesirseosufltWsa"sohbitnaginteodnbWyotrhkesCe-m8p/lGoCyee mLeLth(oEdI.D"08(0E7x1h9i-b2i4t)J,JM(EMID(0E8I0D702769-33812)-8S5e)e aanlsdoNENxhi(bEiItDs0K79K38(6E)I)DOSO717-15), truly yours, ) AA, / A! 212 Rbert A. Bilott RAB:mdm Enclosures cei Dr. Charles M. Auer (USEPA OPPT) Mary Dominiak (USEPA OPPT) (for (w/o encls.) inclusion in (leer by AR-226) telecopy) (w/encls. (letter by telecopy) Jennifer Seed (USEPA) (w/encls.) R. Edison Hill, Esq. (w encls.) (letter by telecopy - enclosures by hard copy) Larry A. Winter, Esq. (w/ encls.) Gerald J. Rapien, Esq. (w/o encls.) wisi 000011